Immune-based Therapies
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 January 9 [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition…
Read MoreA novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing
Scientific Reports 2025 November 21 [Link] Yang Liu, Yang Yang, Songlin An, Hua Wan, Minghao Zhang, Ruihong Yin, Weiting Zhao, Li Huang, Yunshan Zhao, Chenggang Li Abstract Malignant mesothelioma (MM) is a rare, aggressive cancer with poor outcomes due to its heterogeneity and therapy resistance. Patient-derived organoids (PDOs) have emerged as a promising tool for…
Read MoreComprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma
Clinical and Experimental Medicine 2025 November 18 [Link] Jun Li, Hongye He, Yutao Zhang, Muhammad Salman Azhar, Yongxiang Wang Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive thoracic malignancy primarily linked to asbestos exposure. Despite advances in research, the prognosis of MPM remains poor, and there is a lack of efficient and precise…
Read MoreUse of Patient-Derived Organoids for Pleural Mesothelioma 3D modelling
American Journal of Physiology Lung Cellular and Molecular Physiology 2025 October 29 [Link] Luca Volpini, Federica Monaco, Elisabetta Casalone, Elton Jalis Herman, Rebecca Filomena, Sandra Manzotti, Olga Strogovets, Gianluca Moroncini, Matteo Mozzicafreddo, Antonella Poloni, Elena Marinelli Busilacchi, Francesca Gonnelli, Francesca Barbisan, Gaia Goteri, Lina Zuccatosta, Martina Bonifazi, Giuseppe Matullo, Jiri Neuzil, Lory Santarelli, Najib M…
Read MoreDiscovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma
Lung Cancer 2025 September 28 [Link] Jasper H L T van Genugten, Daniel Faulkner, Jens C Hahne, Charlotte Poile, Lodewyk Wessels, Dean A Fennell, Paul Baas Abstract Background: Malignant pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. Although first-line nivolumab plus ipilimumab improves outcomes for some patients, a majority fail to respond.…
Read MoreEfficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of diffuse pleural mesothelioma: a systematic review and meta-analysis
Frontiers in Immunology 2025 September 2 [Link] Peiyuan Sun, Dandan Song, Ning Ma, Shufu Hou, Lei Liu, Jing Gao, Yanyan Tian Abstract Background: While clinical trials confirm the therapeutic value of PD-1/PD-L1 and CTLA-4 inhibitors in diffuse pleural mesothelioma, their real-world safety and efficacy profiles remain incompletely defined. This meta-analysis synthesizes clinical evidence to comprehensively…
Read MorePerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J Battafarano, Russell K Hales, Joseph Friedberg, Boris Sepesi, Julie S Deutsch, Tricia Cottrell, Janis…
Read MorePleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
MedComm 2025 September 1 [Link] Libo Zhang, Meijuan Huang Abstract Pleural mesothelioma (PM) presents significant challenges in clinical management, with current treatment options such as chemotherapy, anti-angiogenic therapies, and immunotherapies only modestly extending progression-free survival (PFS) and overall survival (OS). Another relevant reason is the absence of subsequent-line therapy strategies following progression of PM after…
Read MoreEfficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching
International Journal of Cancer 2025 September 2 [Link] Xin-Li Liang, Yan-Dong Su, Yu-Bin Fu, Yang Yu, Xin-Bao Li, Zhong-He Ji, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li Abstract To investigate the efficacy of postoperative immunotherapy in patients with malignant peritoneal mesothelioma (MPM) after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).…
Read MoreCDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi Abstract Introduction: Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune…
Read More
Skip to content